Flotek Industries

FTK on NYSE. Flotek sells chemistry and data services to oil and gas producers. Market value $919m.

Watch this stockFree. We tell you when something changes.

Price checks use the past 12 months to September 2026. Some use the latest annual report instead, as marked. Quality checks use five annual reports, the latest for the year to December 2025.

Cash flow or capital spending isn't reported, so free cash flow is unknown.

Should I look at this?

Worth a closer look

Read what could go wrong

This is not advice. Check the numbers below.

Compare with another stock

Cash yield
annual report to December 2025
n/a

We could not compute this from the filings.

Price to profit
past 12 months to September 2026
17.7×full

You pay 17.7 years of operating profit for the business. The average large US company costs around 18.

Return on capital
five annual reports to December 2025
10.6%five-year median

Each dollar kept in the business earns 11 cents a year. Above 10 is good.

Quality score: 72 of 100. Price score: 61 of 100. Our list needs 70 on quality and 60 on price.

$21.67 a share, 64% above its 1-year low

Over the past year the price has ranged from $13.19 to $39.67.

Pays no dividend

Prices from Friday’s close (20 November).

Five years of cash, in billions

-0.0
-0.0
n/a
n/a
n/a
20212022202320242025
Revenue
$43m$136m$188m$187m$237m
Operating margin
-72.7%-26.0%12.3%6.5%9.8%
Debt to equity
0.241.080.000.000.36
Shares outstanding
0.08bn0.03bn0.03bn0.03bn0.04bn

Health checks

  • Free cash flow positive0 of 2 years
  • Accounting looks honest (Beneish)Not enough data
  • Financial strength (Piotroski)4 of 9
  • Profit backed by cash (accruals)No
  • Debt0.36× equity
  • Revenue growth, five yearsStrong, 34.9% a year
  • Buying back its own sharesYes, 53% fewer since 2021

The quarter to September 2026

How the business did, compared with the same quarter a year earlier.

  • Sales: $114 million last quarter, up 104% on a year ago.
  • Profit: $13 million, down 35% on a year ago.
  • It keeps 13 cents of each $1 of sales as operating profit, up from 10 cents a year earlier.
  • 1% more shares than a year ago. Each share owns a bit less of the company.
  • Sales grew on a year ago in each of the last 4 quarters.
Sales by quarter
Sales by quarter
Quarter toAmount
December 2024$51m
March 2025$55m
June 2025$58m
September 2025$56m
December 2025$68m
March 2026$70m
June 2026$99m
September 2026$114m
Profit by quarter
Profit by quarter
Quarter toAmount
December 2024$4m
March 2025$5m
June 2025$2m
September 2025$20m
December 2025$3m
March 2026$5m
June 2026$10m
September 2026$13m

From the company's quarterly reports to the SEC.

Dates

Next results (estimated)
n/a
Last annual report (10-K)
16 March 2026
Next quarterly (estimated, 10-Q)
5 February 2027

Who owns it

3 long-term investors we follow own it, up from 2 last quarter. 113 funds in all.

Jun '25
Dec '25
Jun '26
Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

1 investor owns more than 5%.

  • ProFrac Holding Corp.
    Insider or founder
    at least 54.5%−6.6 pts
    (filed with 3 related holders)
    Since 11 September 2026
    What they said

    Item 4 of the Schedule 13D is hereby amended to include the following: On September 11, 2026, a lender under that certain Term Loan Credit Agreement, dated December 27, 2023, by and among Alpine Holding II, LLC ("Alpine Holding"), PF Proppant Holding, LLC, the subsidiary…

    Read the filing

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

In the last 12 months, 1 insider bought $34m of shares on the open market. 2 sold $2m.

  • Agadi Harshavardhan V
    Director
    Sold
    Date
    19 November 2026
    Shares
    14,873
    Price
    $25.67
    Value
    $381,830
  • Agadi Harshavardhan V
    Director
    Sold
    Date
    18 November 2026
    Shares
    33,377
    Price
    $25.32
    Value
    $844,942
  • Agadi Harshavardhan V
    Director
    Sold
    Date
    17 November 2026
    Shares
    6,750
    Price
    $25.02
    Value
    $168,882
  • Agadi Harshavardhan V
    Director
    Sold
    Date
    13 November 2026
    Shares
    15,000
    Price
    $25.27
    Value
    $379,043
  • Wilks Matthew
    Director
    Bought
    Date
    11 September 2026
    Shares
    1,319,493
    Price
    $26.01
    Value
    $34m
  • CLEMENT JAMES BOND
    Chief Financial Officer
    Sold
    Date
    18 May 2026
    Shares
    12,554
    Price
    $20.08
    Value
    $252,084

From Form 4 filings: insiders must report trades in their own company's shares within two days.

Warning signs in its filings

Problems the company itself reported to the SEC, in its own words.

None of the serious warning signs we check for were found. 1 thing worth knowing.

We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.

We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 16 Mar 2026, plus the 10-Q filed 6 Nov 2026 and 10 later 8-Ks.

  • One big customer

    Worth knowing

    One customer brings in a big share of sales: 62% last year. Losing that customer would hurt.

    “The Company derived 62% and 62% of its revenue for the years ended December 31, 2025 and 2024, respectively, from ProFrac Services and ProFrac GDM.”

    From the 10-K filed 16 March 2026, Item 1A. Risk Factors. Read it in the filing

A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.

What could go wrong

  • Profits run ahead of cash.

Whether the price already reflects the risks is what the deep dive is for.

What changed in the risks this year

Companies must list what could hurt them each year. These are the parts that changed since last year’s report.

  • If we fail to maintain proper and effective internal controls over financial reporting, our ability to produce accurate and timely financial statements could be impaired.

    Could happen
    Pursuant to Section 404(a) of the Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley Act”), our management is required to report upon the effectiveness of our internal control over financial reporting. We are an “accelerated filer” with respect to this Annual Report. As such, Section 404(b) of the Sarbanes-Oxley Act requires our independent auditors to express an opinion on our internal control over financial reporting. Ensuring that we have adequate internal controls in place so that we can produce accurate financial statements on a timely basis is a costly and time-consuming effort that will need to be evaluated frequently. If we are unable to maintain effective internal control over financial reporting, we may not have adequate, accurate or timely financial information, our independent registered public accounting firm may issue a report that is adverse, and we may be unable to meet our reporting obligations as a public company or comply with the requirements of the SEC or the Sarbanes-Oxley Act. This could result in a restatement of our financial statements, the imposition of sanctions, including the inability of registered broker dealers to make a market in our common stock, or investigation by regulatory authorities. Any such action or other negative results caused by our inability to meet our reporting requirements or comply with legal and regulatory requirements or by disclosure of an accounting, reporting or control issue could adversely affect the trading price of our securities and our business.
    Read more
  • Changes in U.S. trade policy and the impact of tariffs may have a material adverse effect on our business and results of operations.

    Could happen
    Our CT segment requires access to various chemicals, many of which are produced in the U.S., but some of which contain international components or are sourced internationally. Our DA segment requires access to certain instruments and components, which are produced in whole or in part outside the U.S. Any imposition of or increase in tariffs on imports of these materials, as well as corresponding price increases for such materials available domestically, could increase our costs. To the extent that we are unable to pass all or any of such cost increases on to our customers, such cost increases could adversely affect our returns on investment. Higher materials costs could also diminish our ability to develop new products at acceptable returns, particularly during times of economic uncertainty, and limit our ability to pursue growth opportunities.
    Read more
  • • If we fail to maintain proper and effective internal controls over financial reporting, our ability to produce accurate and timely…

    Could happen
    • If we fail to maintain proper and effective internal controls over financial reporting, our ability to produce accurate and timely financial statements could be impaired;
  • If we fail to maintain proper and effective internal controls over financial reporting, our ability to produce accurate and timely financial statements could be impaired.

    Could happen
    Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations, or cash flows. If we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm determines we have a material weakness or significant deficiency in our internal control over financial reporting, investors may lose confidence in the accuracy and completeness of our financial reports, the market price of our common stock could decline, and we could be subject to sanctions or investigations by Nasdaq, the NYSE, or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.
    Read more
  • Changes in U.S. trade policy and the impact of tariffs may have a material adverse effect on our business and results of operations.

    Could happen
    In addition, tariffs or other trade restrictions may lead to continuing uncertainty and volatility in U.S. and global financial and economic conditions and commodity markets, declining consumer confidence, significant inflation and diminished expectations for the economy, and ultimately reduced demand for our and our customers’ products and services. Such conditions could have a material adverse impact on our business, results of operations and cash flows. Also, disruptions and volatility in the financial markets may lead to adverse changes in the availability, terms and cost of capital. Such adverse changes could increase our costs of capital and limit our access to external financing sources to fund acquisitions, capital projects, or refinancing of our existing debt on similar terms, which could in turn reduce our cash flows and limit our ability to pursue growth opportunities.
    Read more

Read it in the annual report

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from

It just passed both our tests. The deep dive checks what the numbers can't.

Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.